187 related articles for article (PubMed ID: 2879793)
1. Malaria transmission-blocking immunity induced by natural infections of Plasmodium vivax in humans.
Mendis KN; Munesinghe YD; de Silva YN; Keragalla I; Carter R
Infect Immun; 1987 Feb; 55(2):369-72. PubMed ID: 2879793
[TBL] [Abstract][Full Text] [Related]
2. Current developments in malaria transmission-blocking vaccines.
Stowers A; Carter R
Expert Opin Biol Ther; 2001 Jul; 1(4):619-28. PubMed ID: 11727498
[TBL] [Abstract][Full Text] [Related]
3. Target antigens of transmission blocking immunity of Plasmodium vivax malaria. Characterization and polymorphism in natural parasite isolates.
Premawansa S; Peiris JS; Perera KL; Ariyaratne G; Carter R; Mendis KN
J Immunol; 1990 Jun; 144(11):4376-83. PubMed ID: 1692862
[TBL] [Abstract][Full Text] [Related]
4. Transmission blocking malaria vaccines.
Carter R
Vaccine; 2001 Mar; 19(17-19):2309-14. PubMed ID: 11257353
[TBL] [Abstract][Full Text] [Related]
5. Immunity to sexual stages of human malaria parasites: immune modulation during natural infections, antigenic determinants, and the induction of transmission-blocking immunity.
Targett G
Scand J Infect Dis Suppl; 1990; 76():79-88. PubMed ID: 1714627
[TBL] [Abstract][Full Text] [Related]
6. Target antigens in malaria transmission blocking immunity.
Carter R; Miller LH; Rener J; Kaushal DC; Kumar N; Graves PM; Grotendorst CA; Gwadz RW; French C; Wirth D
Philos Trans R Soc Lond B Biol Sci; 1984 Nov; 307(1131):201-13. PubMed ID: 6151684
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal and polyclonal antibodies both block and enhance transmission of human Plasmodium vivax malaria.
Peiris JS; Premawansa S; Ranawaka MB; Udagama PV; Munasinghe YD; Nanayakkara MV; Gamage CP; Carter R; David PH; Mendis KN
Am J Trop Med Hyg; 1988 Jul; 39(1):26-32. PubMed ID: 3041855
[TBL] [Abstract][Full Text] [Related]
8. Transmission immunity in malaria: reflections on the underlying immune mechanisms during natural infections and following artificial immunization.
Carter R; Mendis K
Mem Inst Oswaldo Cruz; 1992; 87 Suppl 3():169-73. PubMed ID: 1364201
[TBL] [Abstract][Full Text] [Related]
9. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
Miura K; Keister DB; Muratova OV; Sattabongkot J; Long CA; Saul A
Malar J; 2007 Aug; 6():107. PubMed ID: 17686163
[TBL] [Abstract][Full Text] [Related]
10. Immune responses against sexual stages of Plasmodium vivax during human malarial infections in Sri Lanka.
Carter R; Mendis KN
Parassitologia; 1991 Apr; 33(1):67-70. PubMed ID: 1688139
[TBL] [Abstract][Full Text] [Related]
11. Development of malaria vaccines that block transmission of parasites by mosquito vectors.
Hisaeda H; Yasutomo K
J Med Invest; 2002 Aug; 49(3-4):118-23. PubMed ID: 12323000
[TBL] [Abstract][Full Text] [Related]
12. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy.
Kongkasuriyachai D; Bartels-Andrews L; Stowers A; Collins WE; Sullivan J; Sattabongkot J; Torii M; Tsuboi T; Kumar N
Vaccine; 2004 Aug; 22(23-24):3205-13. PubMed ID: 15297075
[TBL] [Abstract][Full Text] [Related]
13. The Plasmodium yoelii microgamete surface antigen (PyMiGS) induces anti-malarial transmission blocking immunity that reduces microgamete motility/release from activated male gametocytes.
Tachibana M; Ishino T; Tsuboi T; Torii M
Vaccine; 2018 Nov; 36(49):7463-7471. PubMed ID: 30420038
[TBL] [Abstract][Full Text] [Related]
14. Efficacy model for mosquito stage transmission blocking vaccines for malaria.
Saul A
Parasitology; 2008 Nov; 135(13):1497-506. PubMed ID: 18257944
[TBL] [Abstract][Full Text] [Related]
15. Malaria vaccine.
Khurana SK; Talib VH
Indian J Pathol Microbiol; 1996 Dec; 39(5):433-41. PubMed ID: 9002371
[TBL] [Abstract][Full Text] [Related]
16. Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes.
Arakawa T; Tsuboi T; Kishimoto A; Sattabongkot J; Suwanabun N; Rungruang T; Matsumoto Y; Tsuji N; Hisaeda H; Stowers A; Shimabukuro I; Sato Y; Torii M
Vaccine; 2003 Jul; 21(23):3143-8. PubMed ID: 12804841
[TBL] [Abstract][Full Text] [Related]
17. Diversity of Plasmodium vivax-induced antigens on the surface of infected human erythrocytes.
Mendis KN; Ihalamulla RI; David PH
Am J Trop Med Hyg; 1988 Jan; 38(1):42-6. PubMed ID: 3277464
[TBL] [Abstract][Full Text] [Related]
18. Functional Conservation of P48/45 Proteins in the Transmission Stages of
Cao Y; Hart RJ; Bansal GP; Kumar N
mBio; 2018 Sep; 9(5):. PubMed ID: 30181253
[TBL] [Abstract][Full Text] [Related]
19. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes.
Hisaeda H; Stowers AW; Tsuboi T; Collins WE; Sattabongkot JS; Suwanabun N; Torii M; Kaslow DC
Infect Immun; 2000 Dec; 68(12):6618-23. PubMed ID: 11083773
[TBL] [Abstract][Full Text] [Related]
20. Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate.
Tachibana M; Sato C; Otsuki H; Sattabongkot J; Kaneko O; Torii M; Tsuboi T
Vaccine; 2012 Feb; 30(10):1807-12. PubMed ID: 22245309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
